Lipoprotein(a): an Important Consideration for DAPT Therapy After PCI
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Tsironis L, Mitsios J, Milionis H, Elisaf M, Tselepis A
. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004; 63(1):130-8.
DOI: 10.1016/j.cardiores.2004.03.005.
View
2.
Zhu P, Tang X, Song Y, Zhang Y, Gao L, Gao Z
. Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention. Platelets. 2020; 32(5):684-689.
DOI: 10.1080/09537104.2020.1802412.
View
3.
Barre D
. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res. 2006; 119(5):601-7.
DOI: 10.1016/j.thromres.2006.04.013.
View
4.
Podrez E, Byzova T, Febbraio M, Salomon R, Ma Y, Valiyaveettil M
. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007; 13(9):1086-95.
PMC: 3042888.
DOI: 10.1038/nm1626.
View
5.
Cui K, Wu S, Yin D, Song W, Wang H, Zhu C
. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiol J. 2023; 31(1):32-44.
PMC: 10919557.
DOI: 10.5603/cj.93062.
View